Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers

Fig. 5

Effect of PS-targeting and anti-PD-1 therapies on TILs in E0771 and EMT-6 tumors. a Mice with E0771 tumors were treated on days 10, 14, 17, 21, and 25 post implantation with single antibody treatments or a combination of mch1N11 and anti-PD-1. Five tumors from each treatment group were excised on day 26 and single-cell preparations were stained with antibodies specific to CD45+, CD8+, CD4+, and CD3+. Data are expressed as the group median and percentages of an individual animal positive for a specific surface marker by FACS analysis. CD8+, CD3+, and CD4+ cells were all subpopulations of CD45+ cells. b Mice with EMT-6 tumors were treated on days 10, 14, 17, 21, and 25 post implantation with single antibody treatments or a combination of mch1N11 and anti-PD-1. Five tumors from each treatment group were excised on day 26 and single-cell preparations were stained with antibodies specific to CD45+, CD8+, CD4+, and CD3+. Data are expressed as the group median and percentages of individual animal positive for a specific for a surface marker by FACS analysis. CD8+, CD3+, and CD4+ cells were all subpopulations of CD45+ cells

Back to article page
\